Your browser doesn't support javascript.
loading
Patterns of Pre-exposure Prophylaxis (PrEP) Use in a Population Accessing PrEP in Jackson, Mississippi.
Chase, Erin; Mena, Leandro; Johnson, Kendra L; Prather, Mariah; Khosropour, Christine M.
Afiliación
  • Chase E; Department of Epidemiology, Harborview Medical Center, University of Washington, 325 Ninth Avenue, Box 359777, Seattle, WA, 98104, USA.
  • Mena L; University of Mississippi Medical Center, Jackson, MS, USA.
  • Johnson KL; University of Mississippi Medical Center, Jackson, MS, USA.
  • Prather M; University of Mississippi Medical Center, Jackson, MS, USA.
  • Khosropour CM; Department of Epidemiology, Harborview Medical Center, University of Washington, 325 Ninth Avenue, Box 359777, Seattle, WA, 98104, USA. ckhosro@uw.edu.
AIDS Behav ; 27(4): 1082-1090, 2023 Apr.
Article en En | MEDLINE | ID: mdl-36094635
ABSTRACT
Pre-exposure prophylaxis (PrEP) persistence is suboptimal in the United States. In the Deep South, a region with high rates of new HIV diagnosis, patterns of PrEP discontinuation remain unexplored. We evaluated data from a clinic-based PrEP program in Jackson, Mississippi and included patients initiating PrEP between August 2018 and April 2021. We considered patients to have a gap in PrEP coverage if they had at least 30 days without an active PrEP prescription; those who restarted PrEP after 30 days were classified as 'stopped and restarted' and those who never obtained a new PrEP prescription were classified as 'stopped and did not restart'. Patients without a gap in coverage were considered 'continuously on PrEP'. We estimated median time to first PrEP discontinuation and examined factors associated with time to first PrEP discontinuation. Of 171 patients who received an initial 90-day PrEP prescription; 75% were assigned male at birth and 74% identified as Black. The median time to first discontinuation was 90 days (95% CI 90-114). Twenty-two percent were continuously on PrEP, 28% stopped and restarted (median time off PrEP = 102 days), and 50% stopped and did not restart. Associations with early PrEP stoppage were notable for patients assigned sex female vs male (adjusted hazard ratio [aHR] = 1.6, 95% CI 1.0-2.5) and those living over 25 miles from clinic vs. 0-10 miles (aHR 1.89, 95% CI 1.2-3.0). Most patients never refilled an initial PrEP prescription though many patients re-started PrEP. Interventions to improve persistence and facilitate re-starts are needed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Fármacos Anti-VIH / Profilaxis Pre-Exposición Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male / Newborn País/Región como asunto: America do norte Idioma: En Revista: AIDS Behav Asunto de la revista: CIENCIAS DO COMPORTAMENTO / SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Fármacos Anti-VIH / Profilaxis Pre-Exposición Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male / Newborn País/Región como asunto: America do norte Idioma: En Revista: AIDS Behav Asunto de la revista: CIENCIAS DO COMPORTAMENTO / SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos